Q&A: NYU Langone Medical Center's Harvey Pass on miR-29c* and Mesothelioma Prognosis
February 18, 2010
Q&A: NYU Langone Medical Center's Harvey Pass on miR-29c* and Mesothelioma Prognosis
Researchers from Rosetta Genomics, in collaboration with investigators from NYU Langone Medical Center, this week published data in Cancer Research demonstrating that the microRNA could be used as a prognostic biomarker in patients with mesothelioma.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Rosetta Signs Marketing Deal for Mesothelioma Test with Tort Claims Administration Firm
June 16, 2011 / Gene Silencing News - Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay
May 20, 2013 / GenomeWeb Daily News - Rosetta Settles Dispute over Lab Sale
April 18, 2013 / Gene Silencing News - Rosetta Genomics' 2012 Revenues Nearly Double
March 25, 2013 / GenomeWeb Daily News - Rosetta Genomics Opposes Monsanto Acquisition of Former Subsidiary
March 7, 2013 / Gene Silencing News